CIRS, nasal spray (trial dose)
Timing and details
Loading…
Also known as: Vasoactive intestinal peptide · Vasoactive intestinal polypeptide · Aviptadil · RLF-100
Updated 28 sources
How it is thought to work. Binds the VPAC1 and VPAC2 receptors and raises cAMP inside cells. That relaxes smooth muscle, widens blood vessels and airways, and turns down inflammatory signals; in sarcoidosis it increased regulatory T cells in the lungs. It also acts in the brain's circadian clock.
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Doses shown are what sources report, labelled by origin. Not medical advice.
Full VIP dosage guideEvery titration step in syringe units, missed doses and how to mix.| Water | Strength | 50 mcgdose, units | 100 mcgdose, units | 200 mcgdose, units |
|---|---|---|---|---|
| 5 mg vial | ||||
| 2 mLCompetitor guide | 2.5 mg/mL | 20.02 mL | 40.04 mL | 80.08 mL |
| 10 mg vial | ||||
| 3 mLCompetitor guide | 3.333 mg/mL | 1.50.015 mL | 30.03 mL | 60.06 mL |
Doses shown are what sources report, labelled by origin. Not medical advice.
Calculate with this peptideYour vial, your water, your dose: VIP in syringe units, with the math shown.From clinical trials and regulatory documents.
With 40% of 1,711 penile injections of VIP plus phentolamine; also at the highest IV dose in volunteers
With IV VIP in healthy volunteers
From community reports and dosing guides. Not measured rates.
Among the most reported short-term effects, from blood-vessel widening
How people manage it
Commonly listed; VIP drives intestinal secretion
Mild, among the most reported effects in guides; 77 PeptIQ app logs
Transient, at higher doses in guides; the most logged side effect in the PeptIQ app (83 logs)
Called the main documented risk by one guide; lipase did not rise in the 20-person CIRS trial
How people manage it
The main concern with chronic nasal or inhaled use
History of pancreatitis or raised lipaseCondition
VIP can affect the pancreas; protocols gate on a normal lipase.
Low blood pressureCondition
VIP widens blood vessels and can lower pressure further.
Blood pressure medicinesSubstance
Its blood-pressure effect could add to antihypertensive drugs.
Pregnancy or breastfeedingCondition
Safety not established.
Active cancerCondition
VIP receptors are overexpressed on some tumors, a theoretical concern.
Nasal MARCoNS or ongoing mold exposureCondition
The CIRS protocol says VIP will not work while these remain and requires a negative MARCoNS culture first.
Freezer at -20 C for long-term storage. Other guides say room temperature or the fridge, out of light, or -20 to 4 C.
Fridge at 2 to 8 C, not frozen. Guides disagree on how long: 7 to 14 days, 28 days, 3 to 4 weeks or 30 days. One guide suggests freezing single-use aliquots instead.
Compounded nasal spray: follow the pharmacy's own storage and expiry label.
Mixed with: Bacteriostatic water
Mixing. Applies to research vials only; the nasal spray comes ready-made from a pharmacy. Guides disagree on diluent: one says bacteriostatic water only, another lists sterile saline. Doses are tiny, so draws are only a few units.
Gut repair alongside the systemic anti-inflammatory effect, a common pairing in CIRS treatment.
Immune support in complex CIRS cases; a niche pairing.
Cellular energy support in chronic illness, listed as a common stack by one guide.
The most co-logged compound among PeptIQ app VIP users (12 co-reports). Usage data, not a rationale.
Human data exist but rarely for the way people use it. The CIRS nasal spray rests on one open-label, single-clinic trial of 20 patients published outside PubMed. Inhaled VIP had small open studies in sarcoidosis (n=20) and pulmonary hypertension (n=20 single dose; n=8). The best controlled result is the VIP plus phentolamine ED injection. IV aviptadil failed in COVID respiratory failure (n=461).
On FDA's list of bulk substances under evaluation for compounding.
Not FDA approved as a drug in the US. FDA's 503A list (updated May 14, 2026) puts vasoactive intestinal peptide in Category 1, under evaluation. A 2019 FDA proposed rule would leave VIP off the compounding bulks list; it has not been finalized. IV aviptadil was reported refused a COVID emergency use authorization.
VIP is not named on the WADA 2026 list. S0 covers substances with no current human approval anywhere; aviptadil with phentolamine (Invicorp) is accepted for erectile dysfunction in NHS Scotland, so S0 should not apply on its wording, but no WADA source says so. Guides say Category 1 substances may be compounded meanwhile under FDA's interim policy.
WADA: Not confirmed
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide the body makes in the gut, brain, lungs and elsewhere. It relaxes blood vessels and smooth muscle and helps calm inflammation. Its drug name is aviptadil.
Mostly as a nasal spray for CIRS (mold illness), as the last step of the Shoemaker protocol. In Europe a VIP plus phentolamine injection treats erectile dysfunction. It has also been studied inhaled for pulmonary hypertension and sarcoidosis, and IV for COVID lung failure, where it did not help.
In the 2013 CIRS trial, 20 patients took 50 mcg four times a day by nasal spray for at least 18 months. Clinic protocols describe 50 mcg per spray, often 4 to 8 sprays a day in alternating nostrils, with the first dose given in clinic.
Guides describe 50 to 200 mcg per injection, and 100 mcg twice daily is the most discussed plan. PeptIQ app users most often log 50 to 100 mcg per injection. No trial has tested subQ VIP for these uses.
No. The spray is made by a compounding pharmacy at about 50 mcg per spray and needs no mixing. Research vials are mixed at home and dosed in syringe units. Do not convert one into the other.
It is the final step, step 12 on the protocol's own site. Entry criteria are a normal lipase, a negative MARCoNS nasal culture, a normal HERTSMI-2 building score and a normal VCS test. The site says VIP will not work while exposure or MARCoNS remain.
Lipase is a pancreas marker, and guides treat a rising lipase or new belly pain as the signal to stop. The CIRS protocol requires a normal lipase before starting. In the 2013 trial, lipase did not rise.
Mostly effects of widened blood vessels: flushing, lightheadedness, low blood pressure, a faster heart rate, headache, nausea and loose stools. Flushing came with 40% of injections in the ED trial. Guides flag the pancreas as the key thing to monitor.
About one minute in the blood after an IV infusion, measured in healthy volunteers. That is why guides split doses through the day and why long-acting versions are being developed.
VIP is not an FDA-approved drug. FDA's 503A list, updated May 14, 2026, puts it in Category 1, under evaluation. A 2019 proposed rule would leave it off the bulks list, but that rule is not final, so compounded nasal sprays remain available by prescription.
No. In the TESICO trial of 461 hospitalised patients, IV aviptadil did not improve recovery at day 90 and deaths were similar (38% vs 36%). The trial was stopped for futility.
As Invicorp, an injection of 25 mcg VIP with phentolamine, yes for many men: 75% responded vs 12% on placebo in a controlled trial. It is accepted for restricted use in NHS Scotland after oral drugs fail. It is not the nasal or subQ product.
VIP is not named on the 2026 Prohibited List. The catch-all S0 class only covers substances with no human approval anywhere, and aviptadil is approved in Europe, but WADA has not addressed VIP directly. Athletes should check with their anti-doping agency.
One guide mixes a 10 mg vial with 3 mL of bacteriostatic water for about 3.33 mg/mL, so 50 mcg is 1.5 units, 100 mcg 3 units and 200 mcg 6 units on a U-100 syringe. Such small draws are hard to measure, so check with the calculator.
Guides disagree: 7 to 14 days, 28 days, 3 to 4 weeks or 30 days in the fridge. Pharmacy nasal sprays carry their own expiry date.
Answers come from this site's pages only, with a link to each source.
28 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.